Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology

This article was originally published in Scrip

Executive Summary

Emboldened by results from their existing alliance on mRNA drugs for cardiovascular, metabolic and regenerative disease, AstraZeneca PLC and privately held Moderna Therapeutics LLC have decided to extend their focus to include candidates for the treatment of a range of cancers.

You may also be interested in...



Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO

Moderna is in no rush to conduct an IPO, but the secretive biopharma unicorn gave potential investors in a future offering a glimpse of its 12 programs in or nearing the clinic at J.P. Morgan’s annual conference.

AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.

Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal

Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel